Alien Labs

In May 2026, Alien Labs leaned further into Flower, which held 73.33% share and grew 4.10% year over year while slipping 4.23% month over month, indicating durable demand with short-term deceleration; meanwhile, Pre-Roll rose to 9.91% share with 20.88% YoY growth and 6.31% MoM growth, signaling active trading up within the format. Vapor Pens contracted to 15.95% share with a 10.93% YoY decline and a 6.11% MoM decline, and Concentrates fell to 0.82% share with a 49.80% YoY drop and a 33.50% MoM decline, concentrating revenue risk into fewer categories. With overall brand sales up 1.86% YoY but down 16.35% over 24 months and average price up 2.69% YoY, the mix shift implies a pivot toward higher-volume Flower and faster-growing Pre-Rolls to offset weakness in Vapor Pens and Concentrates, with California Flower rank at 9 reinforcing a scale-first play in the core.

The combination of a 4.10% YoY gain and a 4.23% MoM dip in Flower, alongside Pre-Roll’s 20.88% YoY and 6.31% MoM increases, suggests Alien Labs is trading share from declining Vapor Pens (−10.93% YoY, −6.11% MoM) into combustion-led formats where it holds a top-10 position (Flower rank 9), tilting positioning toward heritage inhalables rather than device-dependent segments. Given Concentrates’ 49.80% YoY and 33.50% MoM declines paired with a 0.82% share, exiting or deprioritizing that niche while defending Flower’s 73.33% share and nurturing Pre-Roll’s 9.91% share would align pricing power (average price +2.69% YoY) with categories where brand equity converts to velocity, implying a focus on depth in California Flower and cross-selling into Pre-Roll to stabilize month-to-month volatility.